All Questions Answered for Ariad Pharmaceuticals Inc.

Shares of Ariad Pharmaceuticals (NASDAQ: ARIA  ) fell today, but on Friday after a tremendous week filled with buyout speculation, Motley Fool health-care analyst David Williamson answered viewer questions about the biotech. Shares rose 12% on Thursday and 25% on Friday, on news of a rumor that Eli Lilly and GlaxoSmithKline have an interest in buying the biotech now that its leukemia drug Iclusig is back on the market, with shares 50% lower than where they were before its safety issues were known.

In this video from Friday's Market Checkup, David looks at two questions about the stock, and the biotech business as a whole. He discusses, why even when battling a very serious disease such as leukemia, some drugs should be reserved as a last resort, and he tells investors how giant companies can mitigate risk by licensing drugs from much smaller companies, such as Ariad.

The best way to play the biotech space today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2811872, ~/Articles/ArticleHandler.aspx, 12/17/2014 11:09:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement